SCHEMBL185178

SCHEMBL185178

CCOC(=O)Cc1csc(NC(=O)C(Oc2ccc(Cl)cc2F)c2ccc(S(=O)(=O)N3CCOCC3)cc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
LMNA P02545 5/20 0.59
TSHR P16473 2/20 0.59
MAPK1 P28482 1/20 0.53
POLB P06746 4/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
GCK P35557 2/20 0.50
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 3/20 0.46
HPGD P15428 1/20 0.46
ATM Q13315 1/20 0.45
MAPT P10636 4/20 0.44
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.43
NOD2 Q9HC29 1/20 0.43
XBP1 P17861 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184580 0.91 GCK (0.58) ALDH1A1LMNATSHRPOLBGCK
SCHEMBL184291 0.88 GCK (0.64) ALDH1A1LMNATSHRMAPK1POLB
SCHEMBL3805122 0.87 SMN1; SMN2 (0.51) LMNAPOLBGCKKMT2AMEN1
SCHEMBL184700 0.82 GCK (0.72) ALDH1A1LMNATSHRGCKMAPT
SCHEMBL184948 0.81 GCK (0.74) ALDH1A1LMNATSHRMAPK1POLB
SCHEMBL184805 0.80 GCK (0.77) ALDH1A1GCKKMT2AMEN1MAPT
SCHEMBL3768825 0.80 GCK (0.58) ALDH1A1GCKKMT2AMEN1MAPT
SCHEMBL3772579 0.79 GCK (0.58) ALDH1A1GCKKMT2AMEN1ATM
SCHEMBL2656033 0.78 KMT2A (0.49) ALDH1A1LMNATSHRMAPK1POLB
SCHEMBL184997 0.77 PPARG (0.63) ALDH1A1TSHRGCKKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US claimed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP claimed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US claimed
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA ALDH1A1 843/4885LMNA 2989/4885TSHR 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.